Abstract: Compounds which are oxadiazaborole derivatives are disclosed, including compounds of the following genus: The compounds are inhibitors of hematopoietic cell kinase (HCK) and exhibit anti-fibrotic and anti-proliferative effects. They are useful in the treatment of a variety of disorders, including a fibrosis or a fibrotic disease, such as renal fibrosis.

Abstract: Compounds which are thiazole and triazole derivatives are disclosed, including compounds of the following genus: The compounds are inhibitors of hematopoietic cell kinase (HCK) and exhibit anti-fibrotic and anti-proliferative effects. They are useful in the treatment of a variety of disorders, including a fibrosis or a fibrotic disease, such as renal fibrosis.

Abstract: An apparatus for inhibiting melatonin synthesis in a horse comprises a blinker having an internal surface of which at least a part is diffusing. A source of light is positioned for direction into the horse's eye by the diffusing-surface. The light source and diffusing surface are configured such that the light directed into the horse's eye is blue.

Abstract: A method for identifying a renal allograft recipient's risk for developing fibrosis of the allograft and allograft loss is disclosed. The method includes identifying the allograft recipient as being at risk for fibrosis of the allograft and allograft loss when the expression level of one or more genes in a preselected gene signature set is altered relative to the expression level of the same one or more genes in a control blood specimen is indicative of the allograft recipient's risk of developing fibrosis of the allograft and allograft loss.

Abstract: Systems and methods for identifying risk of kidney graft failure in a subject are provided. An image of a graft biopsy is obtained, the image representing at least a subset of a plurality of morphological classes including a tissue compartment and inflammation class. The image is inputted into a trained model that identifies, as output, for each morphological class in at least the subset, corresponding objects in the image that fall within the morphological class. For each morphological class, corresponding digital features are generated comprising a first subset of individual feature scores obtained using the objects for the morphological class and a second subset of composite feature scores obtained by combining individual feature scores. Digital features for each morphological class are compared to a reference criterion, thus determining risk of kidney graft failure.

Abstract: Disclosed herein are methods for diagnosing acute cellular rejection (ACR) of an allograft by analysis of predictive gene sets and kits for practicing these methods.

Abstract: Compounds which are oxadiazaborole derivatives are disclosed, including compounds of the following genus: The compounds are inhibitors of hematopoietic cell kinase (HCK) and exhibit anti-fibrotic and anti-proliferative effects. They are useful in the treatment of a variety of disorders, including a fibrosis or a fibrotic disease, such as renal fibrosis.

Abstract: A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstitial fibrosis and tubular atrophy (IF/TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.

Abstract: Disclosed herein are gene signature sets expressed by kidney allograft recipients prior to transplant that determine the risk for acute rejection (AR) post-transplant and methods of using the gene signature sets for identifying renal allograft recipients at risk for acute rejection. Also disclosed herein are kits for use in the invention which comprise primer pairs for the gene signature sets.

Abstract: Disclosed herein are methods for diagnosing acute cellular rejection (ACR) of an allograft by analysis of predictive gene sets and kits for practicing these methods.

Abstract: Compounds which are thiazole and triazole derivatives are disclosed, including compounds of the following genus: The compounds are inhibitors of hematopoietic cell kinase (HCK) and exhibit anti-fibrotic and anti-proliferative effects. They are useful in the treatment of a variety of disorders, including a fibrosis or a fibrotic disease, such as renal fibrosis.

Abstract: Disclosed herein are gene signature sets expressed by kidney allograft recipients prior to transplant that determine the risk for acute rejection (AR) post-transplant and methods of using the gene signature sets for identifying renal allograft recipients at risk for acute rejection. Also disclosed herein are kits for use in the invention which comprise primer pairs for the gene signature sets.

Abstract: A method for identifying the risk of developing Chronic Allograft Nephropathy (CAN) in a patient that received a kidney transplant from a donor which comprises identifying the race of the donor; determining the levels of SHROOM 3 expression in a kidney biopsy specimen obtained from the patient at a predetermined time after transplant; comparing the level of SHROOM 3 expression in the biopsy specimen with the levels of SHROOM 3 expression in a control; determining if the level of SHROOM 3 expression in the allograft is significantly higher than in the control, and diagnosing the patient as being at risk for CAN if the level of SHROOM 3 expression in the specimen is significantly higher than in the control.

Abstract: A method for identifying the risk of developing Chronic Allograft Nephropathy (CAN) in a patient that received a kidney transplant from a donor which comprises identifying the race of the donor; determining the levels of SHROOM 3 expression in a kidney biopsy specimen obtained from the patient at a predetermined time after transplant; comparing the level of SHROOM 3 expression in the biopsy specimen with the levels of SHROOM 3 expression in a control; determining if the level of SHROOM 3 expression in the allograft is significantly higher than in the control, and diagnosing the patient as being at risk for CAN if the level of SHROOM 3 expression in the specimen is significantly higher than in the control.

Abstract: A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstutial fibrosis and tubular atrophy (IF/TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.

Abstract: An apparatus for inhibiting melatonin synthesis in a horse comprises a blinker having an internal surface of which at least a part is diffusing. A source of light is positioned for direction into the horse's eye by the diffusing-surface. The light source and diffusing surface are configured such that the light directed into the horse's eye is blue.

Abstract: A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstutial fibrosis and tubular atrophy (IF/TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.

Abstract: An apparatus for inhibiting melatonin synthesis in a horse comprises a blinker having an internal surface of which at least a part is diffusing. A source of light is positioned for direction into the horse's eye by the diffusing-surface. The light source and diffusing surface are configured such that the light directed into the horse's eye is blue.

Abstract: Disclosed herein is a method for diagnosing a renal allograft recipient's risk for developing fibrosis of the allograft and allograft loss. The method includes determining the expression levels of certain microRNAs, which have been determined to be predictive of an allograft recipient's risk. Also disclosed herein is a method of treating a renal allograft recipient to inhibit fibrosis of the allograft and allograft loss, as well as kits for use in the methods disclosed herein.

Abstract: A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the kidney transplant recipient; measuring the level of clusterin in the urine sample; comparing the level of clusterin in the patient sample to the level of clusterin in a control sample from the urine of a non-fibrotic kidney transplant recipient; diagnosing a kidney transplant recipient with a clusterin level that is significantly higher than the clusterin level in the control as being at an increased risk of developing interstitial fibrosis or tubular atrophy.